A phase I/IIa study assessing single and multiple doses of hepatitis C virus (HCV) non-nucleoside polymerase inhibitor IDX375 in healthy and genotype 1 HCV-infected subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2011
At a glance
- Drugs IDX 375 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 26 Oct 2011 Results will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2011)
- 22 Mar 2011 Status changed from recruiting to completed.
- 28 Feb 2011 Top-line results reported in a Idenix Pharmaceuticals media release.